About FDA
Cumulative percentage of required workplace inspection completed within the FY
Cumulative FY 2012 Target: 100% of 530 inspections by 9/30/2012
Dictionary: RCRM employees perform periodic ESH surveys and audits to identify deficiencies and implement corrective procedures or abatement actions. RCRM also inspects and monitors building ventilation and exhaust systems, and makes recommendations, where necessary, to decrease the possibility of workplace air contamination. Additionally, RCRM inspects and provides recommendations for any other safety compliance issues.
Safety and Environmental Compliance inspections help to not only make the FDA employees safe, but also allow for research to be conducted in a safe environment.
Fiscal Year - 2012
Cumulative FY 2012 Target: 100% of 530 inspections by 9/30/2012
| Time | Target | Cumulative Percent |
|---|---|---|
| Oct 2011 | N/A | 3 |
| Nov 2011 | N/A | 5 |
| Dec 2011 | N/A | 13 |
| Jan 2012 | N/A | 16 |
| Feb 2012 | N/A | 18 |
| Mar 2012 | N/A | 27 |
| Apr 2012 | N/A | 29 |
| May 2012 | N/A | 31 |
| Jun 2012 | N/A | TBD |
| Jul 2012 | N/A | TBD |
| Aug 2012 | N/A | TBD |
| Sep 2012 | N/A | TBD |
FY 2012 YTD: 31%
Cumulative number of workplace inspections conducted within the FY
Fiscal Year - 2012
| Time | Cumulative Monthly Target | Cumulative Number |
|---|---|---|
| Oct 2011 | N/A | 14 |
| Nov 2011 | N/A | 29 |
| Dec 2011 | N/A | 71 |
| Jan 2012 | N/A | 83 |
| Feb 2012 | N/A | 98 |
| Mar 2012 | N/A | 141 |
| Apr 2012 | N/A | 153 |
| May 2012 | N/A | 166 |
| Jun 2012 | N/A | TBD |
| Jul 2012 | N/A | TBD |
| Aug 2012 | N/A | TBD |
| Sep 2012 | N/A | TBD |
FY 2012 YTD: 166
Glossary
ESH
Environmental, Safety, and Health
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.







